S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
Log in

ASTELLAS PHARMA/ADR News Headlines (OTCMKTS:ALPMY)

$17.10
+0.02 (+0.12 %)
(As of 12/12/2019 04:00 PM ET)
Today's Range
$16.97
Now: $17.10
$17.12
50-Day Range
$15.80
MA: $16.82
$17.41
52-Week Range
$12.41
Now: $17.10
$17.50
Volume51,923 shs
Average Volume75,419 shs
Market Capitalization$32.30 billion
P/E Ratio16.44
Dividend Yield1.81%
Beta0.78

Headlines

ASTELLAS PHARMA/ADR (OTCMKTS ALPMY) News Headlines

Source:
DateHeadline
Q3 2020 EPS Estimates for ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Lifted by Jefferies Financial GroupQ3 2020 EPS Estimates for ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Lifted by Jefferies Financial Group
www.americanbankingnews.com - December 12 at 6:41 AM
Astellas Pharma Inc. -- Moodys reviews Astellas Pharmas A1 ratings for downgradeAstellas Pharma Inc. -- Moody's reviews Astellas Pharma's A1 ratings for downgrade
finance.yahoo.com - December 6 at 9:59 AM
Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative ScienceAstellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science
finance.yahoo.com - December 5 at 12:36 PM
ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Receiving Somewhat Favorable Press Coverage, Study ShowsASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Receiving Somewhat Favorable Press Coverage, Study Shows
www.americanbankingnews.com - December 4 at 11:20 PM
Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual MeetingAstellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting
finance.yahoo.com - December 2 at 11:54 PM
This Gene Therapy Player Just Grabbed A $3 Billion Takeover BidThis Gene Therapy Player Just Grabbed A $3 Billion Takeover Bid
finance.yahoo.com - December 2 at 6:53 PM
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial CancerSeattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
finance.yahoo.com - December 2 at 8:53 AM
Comparing ASTELLAS PHARMA/ADR (ALPMY) and The CompetitionComparing ASTELLAS PHARMA/ADR (ALPMY) and The Competition
www.americanbankingnews.com - November 21 at 9:11 PM
New England Journal of Medicine Publishes Results from Astellas Phase 3 ADMIRAL Trial of XOSPATA® (gilteritinib) in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia(1)New England Journal of Medicine Publishes Results from Astellas' Phase 3 ADMIRAL Trial of XOSPATA® (gilteritinib) in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia(1)
finance.yahoo.com - October 31 at 5:31 PM
U.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP1128 for Patients at Risk for Acute Kidney InjuryU.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP1128 for Patients at Risk for Acute Kidney Injury
finance.yahoo.com - October 28 at 1:51 PM
The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart DrugThe Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug
www.benzinga.com - October 25 at 7:41 AM
European Commission Approves Astellas XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 MutationEuropean Commission Approves Astellas' XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
finance.yahoo.com - October 25 at 7:41 AM
Astellas Pharma Inc. -- Moodys announces completion of a periodic review of ratings of Astellas Pharma Inc.Astellas Pharma Inc. -- Moody's announces completion of a periodic review of ratings of Astellas Pharma Inc.
finance.yahoo.com - October 16 at 1:39 PM
Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene TherapyAstellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy
finance.yahoo.com - October 13 at 9:25 AM
Investors May Want to Follow the Progress of These BiotechsInvestors May Want to Follow the Progress of These Biotechs
finance.yahoo.com - September 23 at 8:27 PM
Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 MutationAstellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
finance.yahoo.com - September 20 at 1:11 PM
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial CancerSeattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - September 16 at 9:29 AM
Astellas Partners with MBC BioLabs to Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery and Research EffortsAstellas Partners with MBC BioLabs to Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts
finance.yahoo.com - September 11 at 6:15 PM
Astellas Appoints Chelsea Glinski as National Vice President Oncology SalesAstellas Appoints Chelsea Glinski as National Vice President Oncology Sales
finance.yahoo.com - July 10 at 9:31 AM
Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer studySeattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study
finance.yahoo.com - June 3 at 5:52 PM
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)
finance.yahoo.com - May 30 at 9:32 AM
New Data Show Mirabegron Reduced OAB Symptoms in Men with Benign Prostatic Hyperplasia Currently Treated with TamsulosinNew Data Show Mirabegron Reduced OAB Symptoms in Men with Benign Prostatic Hyperplasia Currently Treated with Tamsulosin
finance.yahoo.com - May 14 at 9:48 AM
Amgen, Astrellas to pay $125 million in fines tied to alleged kickback schemeAmgen, Astrellas to pay $125 million in fines tied to alleged kickback scheme
www.marketwatch.com - April 25 at 6:12 PM
Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probeDrugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe
finance.yahoo.com - April 25 at 6:12 PM
Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage ChemotherapyPhase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy
finance.yahoo.com - April 1 at 9:59 AM
Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Societys Annual Meeting (ENDO)Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society's Annual Meeting (ENDO)
finance.yahoo.com - March 26 at 6:25 PM
Why Ironwood's Shares Climbed 11.7% on WednesdayWhy Ironwood's Shares Climbed 11.7% on Wednesday
finance.yahoo.com - February 13 at 5:40 PM
Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate CancerPhase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
finance.yahoo.com - February 11 at 5:37 PM
Can This Biotech Stock Rival Amgen In Anemia? Analyst Says YesCan This Biotech Stock Rival Amgen In Anemia? Analyst Says Yes
finance.yahoo.com - December 20 at 4:48 PM
Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate CancerAstellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer
finance.yahoo.com - December 20 at 9:31 AM
Astellas Acquires Potenza TherapeuticsAstellas Acquires Potenza Therapeutics
finance.yahoo.com - December 14 at 4:51 PM
Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
finance.yahoo.com - December 3 at 4:30 PM
XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 MutationXOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
finance.yahoo.com - November 29 at 9:50 AM
Astellas Pharma gets U.S. nod for blood cancer treatmentAstellas Pharma gets U.S. nod for blood cancer treatment
finance.yahoo.com - November 28 at 4:41 PM
Astellas Global Health Foundation LaunchesAstellas Global Health Foundation Launches
finance.yahoo.com - November 20 at 4:35 PM
Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual MeetingAstellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 19 at 9:13 AM
Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate CancerAstellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
finance.yahoo.com - September 24 at 9:26 AM
[$$] Astellas Pharma Buys U.K.s Quethera[$$] Astellas Pharma Buys U.K.'s Quethera
finance.yahoo.com - August 10 at 4:26 PM
Astellas Announces Acquisition of QuetheraAstellas Announces Acquisition of Quethera
finance.yahoo.com - August 10 at 9:31 AM
Astellas Is Considering Selling Europe Assets to Raise CashAstellas Is Considering Selling Europe Assets to Raise Cash
finance.yahoo.com - July 18 at 4:16 PM
U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
finance.yahoo.com - July 14 at 4:46 PM
Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor TherapyAstellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
finance.yahoo.com - June 3 at 9:14 AM
Astellas Oncology C3 Prize® Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the WorldAstellas Oncology C3 Prize® Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World
finance.yahoo.com - May 31 at 4:31 PM
How Is Merck’s Hospital Acute Care Segment Positioned?How Is Merck’s Hospital Acute Care Segment Positioned?
finance.yahoo.com - May 30 at 9:30 AM
FDA accepts Astellas marketing application for gilteritinib for AMLFDA accepts Astellas' marketing application for gilteritinib for AML
seekingalpha.com - May 29 at 4:28 PM
Astellas Pharma: FDA To Review NDA For Gilteritinib - Quick FactsAstellas Pharma: FDA To Review NDA For Gilteritinib - Quick Facts
www.nasdaq.com - May 29 at 9:17 AM
U.S. FDA Grants Priority Review to Astellas New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
finance.yahoo.com - May 29 at 9:17 AM
Astellas Announces Abstracts Highlighting Growing Oncology Portfolio to be Presented at 2018 American Society of Clinical Oncology (ASCO) Annual MeetingAstellas Announces Abstracts Highlighting Growing Oncology Portfolio to be Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 17 at 9:43 AM
Astellas Appoints Bernhardt Zeiher, M.D., as New Chief Medical OfficerAstellas Appoints Bernhardt Zeiher, M.D., as New Chief Medical Officer
finance.yahoo.com - May 15 at 4:48 PM
Astellas Pharma : FDA Approves Supplemental NDA For MyrbetriqAstellas Pharma : FDA Approves Supplemental NDA For Myrbetriq
www.nasdaq.com - May 8 at 9:22 AM
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel